Latest real-world evidence presented at WCO-IOF-ESCEO assesses how Evenity (romosozumab) can help to close the treatment gap in osteoporosis – UCB
UCB, announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice. The… read more.
